{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:49:20Z","timestamp":1788274160781,"version":"build-2803163510"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"DOI":"10.7759\/cureus.84880","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:03:54Z","timestamp":1748340234000},"source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab-Induced Hypothyroidism and Diabetes Mellitus: A Rare Case Presentation Post-Treatment"],"prefix":"10.7759","author":[{"given":"Jeevan","family":"Perera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Bhanot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Pembrolizumab. (2011). Accessed. March 3, 2025: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/pembrolizumab."},{"key":"ref2","article-title":"Immune checkpoint inhibitors related endocrine adverse events","author":"Elshimy G","year":"2000","unstructured":"Elshimy G, Raj R, Akturk HK, et al.. Immune checkpoint inhibitors related endocrine adverse events. Endotext [Internet]. Feingold KR, Ahmed SF, Anawalt B, et al. (ed): MDText.com, Inc., South Dartmouth, MA; 2000."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian SL","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015, 27:450-61. 10.1016\/j.ccell.2015.03.001","journal-title":"Cancer Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512383","article-title":"Efficacy of pembrolizumab in advanced melanoma: a narrative review","volume":"24","author":"Rizzetto G","year":"2023","unstructured":"Rizzetto G, De Simoni E, Molinelli E, Offidani A, Simonetti O. Efficacy of pembrolizumab in advanced melanoma: a narrative review. Int J Mol Sci. 2023, 24:12383. 10.3390\/ijms241512383","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-G21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice","volume":"47","author":"Cho YK","year":"2023","unstructured":"Cho YK, Jung CH. Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice. Diabetes Metab J. 2023, 47:757-66. 10.4093\/dmj.2023.0072","journal-title":"Diabetes Metab J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright JJ","year":"2018","unstructured":"Wright JJ, Salem JE, Johnson DB, et al.. Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care. 2018, 41:e150-1. 10.2337\/dc18-1465","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dbi17-0016","article-title":"The adiponectin paradox for all-cause and cardiovascular mortality","volume":"67","author":"Menzaghi C","year":"2018","unstructured":"Menzaghi C, Trischitta V. The adiponectin paradox for all-cause and cardiovascular mortality. Diabetes. 2018, 67:12-22. 10.2337\/dbi17-0016","journal-title":"Diabetes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/349825-pembrolizumab-induced-hypothyroidism-and-diabetes-mellitus-a-rare-case-presentation-post-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:03:55Z","timestamp":1748340235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/349825-pembrolizumab-induced-hypothyroidism-and-diabetes-mellitus-a-rare-case-presentation-post-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.84880","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}